Sociedad Americana de Hirudoterapia

Philippine Food and Drug Administration

DOH-FDA · Philippines · asia pacific

Regulatory jurisdiction profileJurisdictional reference
Medical device clearednational regulator

Philippine FDA (under Department of Health) — leech therapy regulated as a medical device with parallel traditional and alternative medicine pathway under the PITAHC framework.

Regulatory Profile

Agency type
national regulator
Region
asia pacific
Country
Philippines
Leech status
medical device cleared
Last ASH review
2026-05-25

Relevant Regulation Codes

  • Republic Act No. 9711 — Food and Drug Administration Act of 2009
  • Republic Act No. 8423 — Traditional and Alternative Medicine Act (TAMA) of 1997
  • FDA Circular No. 2014-005 (medical-device classification rules)

Prescriber Requirements

  • Professional Regulation Commission (PRC) Board of Medicine–licensed MD
  • PITAHC-accredited traditional medicine practitioners under TAMA scope
  • RN application under physician supervision per Board of Nursing scope

Supply Chain & GMP

FDA Philippines License to Operate (LTO) + Certificate of Product Registration (CPR) for the device. English-language IFU.

Import/Export Rules

FDA-issued import permit + Bureau of Animal Industry (BAI) clearance for live invertebrates. CITES paperwork via Department of Environment and Natural Resources (DENR).

Reimbursement Context

PhilHealth has no dedicated case-rate for leech therapy; inpatient flap salvage absorbed into the relevant case-rate package (e.g., RVS code for flap repair). Private payment prevails outside hospital settings.

ASH Editorial Notes

PITAHC (Philippine Institute of Traditional and Alternative Health Care) is a unique statutory body responsible for accrediting and integrating non-biomedical practices, including hirudotherapy, into the national healthcare system.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.